Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

A Huntington’s trial brings hope and grief

Erin Paterson
Conditions
November 4, 2025
Share
Tweet
Share

It’s been weeks since the news broke of UniQure’s trial successfully slowing the progression of HD, and I still find myself breaking down in tears. I have been going about my life, doing the groceries, going to the gym, cleaning the house, and the tears keep coming unexpectedly. I am happy about the news, but that is not how it feels in my body. I have come to realize I am experiencing grief.

There are so many mixed emotions in the community, and that is completely understandable.

This is the positive story the HD community has been waiting for. UniQure announced that its investigational gene therapy can slow progression of the disease. The therapy is being used in clinical trials to lower huntingtin while also exploring safety. As a clinical trial it not available to the community yet, but this is the first time a disease-modifying treatment has been on the horizon. This is a huge advancement for the HD community and we are all celebrating.

But

We are still in the trenches taking care of our sick loved ones. Whether you are parenting a child with JHD, caregiving for a parent, or supporting multiple people impacted by the disease, the reality of our daily lives has not changed. For many of those we love and care for, this breakthrough has not arrived in time.

There is fear that, if it’s’ approved, this treatment may not be accessible for everyone. We worry that it might not be available in our country, we might not qualify for treatment, we will not be able to afford it, or our symptoms will be too advanced. We also know there are a lot of hurdles to overcome before this treatment reaches the community. It needs to go through peer review and be approved by the FDA, and that’s just in the U.S. Then it has to be approved and rolled out around the world. It feels treacherous to get our hopes up too high.

This announcement brings to mind all of those who have already suffered and lost the battle with this disease. The potential treatment is too late for them, but that doesn’t stop us from wishing that things were different, that we could have them back, that they could have benefitted from this as well. Imagine how different our lives could have been.

Huntington’s disease is a part of our identity. Whether we are gene positive, gene negative, or untested, we have worked really hard to accept our fate in life. This announcement represents a fundamental shift in how we see ourselves. Although the shift is good, it’s uncomfortable. Now there is the possibility of a brighter future, and that can be unsettling because we don’t know what our future looks like anymore.

No matter how this news has impacted you, no matter what emotions you are experiencing, even if you can’t quite identify what you are feeling, it’s OK to feel the way that you do. Your emotions are not wrong.

Living with Huntington’s disease in the family is very complex, and so is thinking about this potential treatment. Not only do we need to consider the impacts for ourselves personally, we also have to think of everyone in our family.

And soon, if we are lucky, and this treatment is approved in the countries where we live, we will face another set of important questions. Do I want to go through this treatment? Is this the right treatment for me? It’s a very personal decision, and everyone has the right to make their own choices around accessing treatment, or not, just as they do with deciding to go through genetic testing or having children who are at risk. This potential treatment involves a lengthy brain surgery. Perhaps now that huntingtin-lowering could be a viable strategy, it will push along other treatments in development, and maybe those won’t be as invasive.

There are so many unknowns.

For now I am focusing on the renewed hope this announcement has given me and trying to shift my thinking from being someone who is 100 percent guaranteed to get HD, because I am gene positive, to someone who just might not. I have to come to terms with this new reality.

I am beyond grateful to everyone who has worked so tirelessly to get us to this point, including all the scientists searching for a treatment, the drug companies investing in finding effective treatments, and the brave individuals who participated not only in this clinical trial but in all the ones that have come before. I am grateful as well for the patient advocacy organizations that have been supporting us along the way, not just with understanding clinical trials but also with the complexity of our everyday lives. We are all part of a wonderful community, and we will be there to support each other no matter what.

Erin Paterson is a writer and the author of Huntington’s Disease Heroes: Inspiring Stories of Resilience from the HD Community and All Good Things: A Memoir About Genetic Testing, Infertility and One Woman’s Relentless Search for Happiness.

ADVERTISEMENT

Prev

How misinformation endangers our progress against preventable diseases [PODCAST]

November 3, 2025 Kevin 0
…
Next

What is professional inertia in medicine?

November 4, 2025 Kevin 0
…

Tagged as: Neurology

Post navigation

< Previous Post
How misinformation endangers our progress against preventable diseases [PODCAST]
Next Post >
What is professional inertia in medicine?

ADVERTISEMENT

More by Erin Paterson

  • Why the words doctors use matter more than they think

    Erin Paterson
  • Embracing the Huntington’s disease community

    Erin Paterson
  • The heartbreaking realities of being a caregiver with Huntington’s disease

    Erin Paterson

Related Posts

  • In the face of uncertainty, choose hope over fear

    Shreya Kumar
  • Tackling trial delays, social inflation, and skeptical jurors in a pandemic world

    Marco Spadacenta, JD
  • A touching tale of hope and uncertainty in the hospital

    Elizabeth Rodriguez
  • Beyond opioids: a new hope for chronic pain relief

    L. Joseph Parker, MD
  • Unsolicited advice from unmatched residency applicants: Hope for the best, plan for the worst

    Katherine Yu, MD and Shaan Somani
  • The emotional side of genetic testing

    Erin Paterson

More in Conditions

  • AI in prior authorization: the new gatekeeper

    Tiffiny Black, DM, MPA, MBA
  • How to keep the soul of medicine alive in a scaling system

    Gerald Kuo
  • How to handle medical gaslighting

    Alan P. Feren, MD
  • Gender bias in medicine: Who deserves to be saved?

    Anonymous
  • Tick-borne disease vaccines: a 2025 update

    Melvin Sanicas, MD
  • AI and human connection: an ethical crisis

    Mohammed Umer Waris, MD
  • Most Popular

  • Past Week

    • The loss of community pharmacy expertise

      Muhammad Abdullah Khan | Conditions
    • Accountable care cooperatives: a community-owned health care fix

      David K. Cundiff, MD | Policy
    • Psychiatrists are physicians: a key distinction

      Farid Sabet-Sharghi, MD | Physician
    • Why the expiration of ACA enhanced subsidies threatens health care access

      Sandya Venugopal, MD and Tina Bharani, MD | Policy
    • Is primary care becoming a triage station?

      J. Leonard Lichtenfeld, MD | Physician
    • A physician’s tribute to his medical technologist wife

      Ronald L. Lindsay, MD | Physician
  • Past 6 Months

    • Direct primary care in low-income markets

      Dana Y. Lujan, MBA | Policy
    • Patient modesty in health care matters

      Misty Roberts | Conditions
    • The U.S. gastroenterologist shortage explained

      Brian Hudes, MD | Physician
    • The Silicon Valley primary care doctor shortage

      George F. Smith, MD | Physician
    • California’s opioid policy hypocrisy

      Kayvan Haddadan, MD | Conditions
    • A lesson in empathy from a young patient

      Dr. Arshad Ashraf | Physician
  • Recent Posts

    • Is primary care becoming a triage station?

      J. Leonard Lichtenfeld, MD | Physician
    • Violence against physicians and the role of empathy

      Dr. R.N. Supreeth | Physician
    • The impact of policy cuts on ableism in health care

      Ahna Shome, MD | Policy
    • How deprescribing in psychiatry offers a path to safer care

      Muhamad Aly Rifai, MD | Meds
    • AI in prior authorization: the new gatekeeper

      Tiffiny Black, DM, MPA, MBA | Conditions
    • Why learning specialists are central to medical education [PODCAST]

      The Podcast by KevinMD | Podcast

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

Leave a Comment

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

ADVERTISEMENT

  • Most Popular

  • Past Week

    • The loss of community pharmacy expertise

      Muhammad Abdullah Khan | Conditions
    • Accountable care cooperatives: a community-owned health care fix

      David K. Cundiff, MD | Policy
    • Psychiatrists are physicians: a key distinction

      Farid Sabet-Sharghi, MD | Physician
    • Why the expiration of ACA enhanced subsidies threatens health care access

      Sandya Venugopal, MD and Tina Bharani, MD | Policy
    • Is primary care becoming a triage station?

      J. Leonard Lichtenfeld, MD | Physician
    • A physician’s tribute to his medical technologist wife

      Ronald L. Lindsay, MD | Physician
  • Past 6 Months

    • Direct primary care in low-income markets

      Dana Y. Lujan, MBA | Policy
    • Patient modesty in health care matters

      Misty Roberts | Conditions
    • The U.S. gastroenterologist shortage explained

      Brian Hudes, MD | Physician
    • The Silicon Valley primary care doctor shortage

      George F. Smith, MD | Physician
    • California’s opioid policy hypocrisy

      Kayvan Haddadan, MD | Conditions
    • A lesson in empathy from a young patient

      Dr. Arshad Ashraf | Physician
  • Recent Posts

    • Is primary care becoming a triage station?

      J. Leonard Lichtenfeld, MD | Physician
    • Violence against physicians and the role of empathy

      Dr. R.N. Supreeth | Physician
    • The impact of policy cuts on ableism in health care

      Ahna Shome, MD | Policy
    • How deprescribing in psychiatry offers a path to safer care

      Muhamad Aly Rifai, MD | Meds
    • AI in prior authorization: the new gatekeeper

      Tiffiny Black, DM, MPA, MBA | Conditions
    • Why learning specialists are central to medical education [PODCAST]

      The Podcast by KevinMD | Podcast

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Leave a Comment

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...